| 2009-09 |
2009 Taipei Biotechnology Awards were granted for PHN131. |
 |
| 2009-09 |
The IND application and the Phase II clinical trial for PHN033 (PH3) was approved by U.S. FDA . |
|
| 2009-08 |
The IND application and the Phase II clinical trial for PHN013 (PG2) was approved by U.S. FDA . |
|
| 2009-05 |
Groundbreaking ceremony was held for PhytoHealth’s sterile superfine drug substance plant for botanical new drugs, the first of its kind in Taiwan. |
|
| 2009-05 |
PhytoHealth was approved for the subsidy under Industrial Technology Development Program for PHN121, the botanically-derived new drug candidate for Hepatitis C. |
|
| 2009-04 |
PhytoHealth received the approval from the Department of Health (DOH) for the phase II clinical trial of PHN031 (PH3) at National Taiwan University Hospital and Chung Gung Memorial Hospital. |
|
| 2009-02 |
PhytoHealth received the National Innovation Awards for the new analgesic candidate- PHN131 from the Institute of Biotechnology and Medicine Industry. |
|
| 2009-02 |
PHN081 (PDC-748) and PHN131 was awarded as the 「Index Case」 by the Taiwanese regulatory authority, Center for Drug Evaluation. |
|
| 2008-11 |
PhytoHealth awarded the Taiwan Healthcare Industry Innovation and Excellence Awards 2008. |
|
| 2008-11 |
PhytoHealth granted the Certificate of Taiwan Intellectual Property Management System (TIPS) |
|
